Oral medicine trial for COVID 19

A Single blind double Armed Clinical study in the management of COVID 19 through Shamanoushadi

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027616

Enrollment

100

Registered

2020-09-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Dashanga gulika & Haridra Khanda: Dose : 2 gulika & 12gm Dosage form : gulika and choorna with sukoshna jala Route of Administration : Oral route Time of Administration : Twice a day

Eligibility

Inclusion criteria

Inclusion criteria: 1. Hospitalized 2. Adults 18 year or older 3. Moderately severe disease (NEWS score 4. SARS-CoV-2 positive nasopharyngeal swab 5. Signed informed consent must be obtained and documented according to ICH GCP, and national/local regulations.

Exclusion criteria

Exclusion criteria: 1. Requiring ICU admission at screening 2. Tinnitus, reduced hearing 3. Visual impairment

Design outcomes

Primary

Measure	Time frame
COVID 19 swab testTimepoint: On lst day, 15th day, 30th day and after 45 days.	—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public ContactDr Prashant A S

Principal, Professor and HOD

drprashanthas@gmail.com9448114773

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026